Great Valley Advisor Group, Inc. Biomarin Pharmaceutical Inc Transaction History

Great Valley Advisor Group, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 16, 2024	SELL	$74.43 - $92.22 $39,671 - $49,153	-533 Reduced 12.43%	3,754 $309,000
Q1 2024 May 03, 2024	SELL	$83.81 - $99.0 $86,156 - $101,772	-1,028 Reduced 19.34%	4,287 $374,000
Q4 2023 Feb 05, 2024	SELL	$76.22 - $98.51 $33,917 - $43,836	-445 Reduced 7.73%	5,315 $512,000
Q2 2023 Aug 10, 2023	SELL	$86.68 - $100.3 $20,369 - $23,570	-235 Reduced 3.92%	5,760 $499,000
Q1 2023 May 02, 2023	SELL	$87.74 - $117.27 $1,667 - $2,228	-19 Reduced 0.32%	5,995 $582,000
Q4 2022 Jan 31, 2023	SELL	$80.93 - $108.63 $7,445 - $9,993	-92 Reduced 1.51%	6,014 $622,000
Q3 2022 Oct 21, 2022	SELL	$82.16 - $96.94 $314,508 - $371,086	-3,828 Reduced 38.53%	6,106 $518,000
Q2 2022 Jul 19, 2022	BUY	$71.48 - $86.85 $424,877 - $516,236	5,944 Added 148.97%	9,934 $823,000
Q1 2022 Apr 20, 2022	BUY	$74.28 - $92.69 $113,277 - $141,352	1,525 Added 61.87%	3,990 $314,000
Q4 2021 Feb 10, 2022	BUY	$71.72 - $91.47 $176,789 - $225,473	2,465 New	2,465 $218,000

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Great Valley Advisor Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Great Valley Advisor Group, Inc. with notifications on news.